Momelotinib May Become ‘No. 1 Choice’ for Second-Line Therapy in Myelofibrosis, Expert Says

Video

Momelotinib continues to show benefit in reducing splenic symptoms and anemia in myelofibrosis in the second-line setting, making it a likely first treatment choice, according to an expert from the University of Texas MD Anderson Cancer Center.

After demonstrating benefit in reducing anemia and splenic symptoms, momelotinib could become the optimal treatment option in the second-line setting for patients with myelofibrosis, according to Srdan Verstovsek, MD, PhD.

During the 2022 American Society of Hematology (ASH) Annual Meeting, CancerNetwork® spoke with Verstovsek, the United Energy Resources, Inc., Professor of Medicine and a hematologist-oncologist at the University of Texas MD Anderson Cancer Center in Houston, about findings from a pooled analysis of 3 phase 3 trials assessing momelotinib in patients with myelofibrosis.

In addition to feeling positive about the agent’s potential FDA approval in June 2023, Verstovsek stated that momelotinib could be the best treatment option for patient in the second-line setting.

Transcript:

When June of 2023 comes where we expect the decision by FDA as to whether [momelotinib should be] approved or not, I hope it will be because the study was really well done. It clearly shows the benefit in anemia and splenic symptoms. [We must quickly] find its place in the management of our patients with myelofibrosis, particularly in the setting the phase 3 randomized study was done in: the second-line setting where we struggle.

We don't have any therapy for anemia. If a patient has low platelets, this drug can be given to [them]. Of course, it can control the spleen if it has major problems. I would say that this drug may become the No. 1 choice of therapy in the second-line setting in myelofibrosis in the very near future.

Reference

Verstovsek S. Momelotinib (MMB) long-term safety: pooled data from three phase 3 randomized-controlled trials (RCTs). Presented at 2022 American Society of Hematology (ASH) Meeting and Exposition; December 10-13, 2022; abstract 4348.

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Related Content